Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 2Prostatic Neoplasms 1Pancreatic cancer, adult 1Ovarian Neoplasms 1Opioid-Related Disorders 1Lymphoma, Follicular 1Lung Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Rituximab 91Cyclophosphamide 31Lenalidomide 28Bendamustine Hydrochloride 25Prednisone 21Vincristine 20obinutuzumab 17Doxorubicin 17fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Prednisolone 9Deoxycholic Acid 9parsaclisib 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × Hematologic Tests × Clear all
NCT05251376 2023-01-19

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

Lyndra Inc.

Phase 1 Withdrawn
Lymphoid

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡